Julie Rubinstein, President and Chief Operating Officer of Adaptive Biotechnologies Corp, filed a Form 4 on November 10, 2026, disclosing option exercises and open-market sales of common stock on November 9 and 10, 2026, carried out under a pre-established Rule 10b5-1 trading plan.

Key Highlights

  • Reporting person: Julie Rubinstein, President and COO of Adaptive Biotechnologies Corp (NASDAQ:ADPT)
  • Option exercises: Two separate exercises of 11,881 shares each (one on Nov 9, one on Nov 10) at an exercise price of $12.14 per share, reducing remaining options to 35,228
  • Shares sold on Nov 9: 1,100 shares at a weighted average of $28.87, 8,381 shares at $30.15, and 2,400 shares at $30.58
  • Shares sold on Nov 10: 9,981 shares at a weighted average of $29.35 and 1,900 shares at $30.41
  • Beneficial ownership after all transactions: 377,802 shares held directly
  • Trading plan: All transactions were made pursuant to a Rule 10b5-1 plan adopted by Rubinstein on November 18, 2025
  • Options exercised: The stock option exercised on both dates was fully vested and exercisable, with an expiration date of March 4, 2032

Rubinstein's Two-Day Exercise and Sale Activity at Adaptive Biotechnologies

According to the filing, Rubinstein exercised stock options and sold common stock of Adaptive Biotechnologies Corp on both November 9 and November 10, 2026. Each day's activity began with the exercise of 11,881 stock options at a conversion price of $12.14 per share (transaction code M), followed by open-market sales (transaction code S). The filing notes that the exercised option was "fully vested and exercisable" with an expiration date of March 4, 2032. Following both days' exercises, the remaining stock options stood at 35,228.

On November 9, 2026, Rubinstein sold shares in three separate tranches: 1,100 shares at a weighted average price of $28.87 (ranging from $28.41 to $29.35), 8,381 shares at a weighted average of $30.15 (ranging from $29.50 to $30.49), and 2,400 shares at a weighted average of $30.58 (ranging from $30.50 to $30.71). On November 10, 2026, two additional sale tranches were reported: 9,981 shares at a weighted average of $29.35 (ranging from $29.00 to $29.95) and 1,900 shares at a weighted average of $30.41 (ranging from $30.22 to $30.68). All prices reported for the sales are weighted averages across multiple sub-transactions.

The filing states that all transactions were "effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025." The filing also notes that Rubinstein undertakes to provide full details on the number of shares sold at each individual price within the stated ranges upon request by Adaptive Biotechnologies, any security holder, or SEC staff. After all reported transactions, Rubinstein's direct beneficial ownership stood at 377,802 shares of common stock.

What Was Disclosed

The Form 4 disclosed option exercises and common stock sales by Adaptive Biotechnologies' President and COO Julie Rubinstein on November 9 and 10, 2026, all conducted under a Rule 10b5-1 plan adopted November 18, 2025, leaving her with 377,802 shares directly held.